autovac

autovac

(ˈɔːtəʊˌvæk)
n
a vacuum pump found in the petrol tank of a car
References in periodicals archive ?
One change that may have almost gone unnoticed to all but the most knowledgeable or keen eyed ale drinkers visiting is the removal of the autovac system of beer dispensing.
Powered by a rechargeable lithiumion battery, the cordless OmniFlex AutoVac automated floor cleaning machine is ideal for scrubbing hard surfaces.
Powered by a rechargeable lithium-ion battery, the cordless OmniFlex AutoVac automated floor cleaning machine is ideal for scrubbing hard surfaces.
The STA 449 F5 Jupiter comes standard with both AutoVac for automatic evacuation and refilling of the measurement system and mass flow controllers (MFCs) for precise control of purge and protective gases.
in downtown Chicago and bought his first AutoVac thermoformer.
The Danish drug developer Pharmexa A/S said on Thursday (28 April) that it had been informed by the US pharmaceuticals company GlaxoSmithKline (GSK) of its decision not to exercise a previously granted right to negotiate a licence agreement on Pharmexa's HER-2 Protein AutoVac vaccine.
The AUTOVAC IO[TM] is a self contained, intraoperative, Whole blood autotransfusion system that allows simple, effective collection and influsion of a patient's blood.
Blood salvage was achieved using Boehringer Laboratories' (Norristown, Pa) Autovac Blood Processing System, adhering to the manufacturer's directions.
Examples of end-cut biopsy guns include the Autovac (Argon Medical, Sugarland, Tex), the Ultra-Vac (MD Tech, Gainesville, Fla) and the Full-Core (Amedic AB, Sollentuna, Sweden).
NORDIC BUSINESS REPORT-13 May 2004-Pharmexa A/S receives European patent for DNA AutoVac technology(C)1994-2004 M2 COMMUNICATIONS LTD http://www.
The AUTOVAC IO[TM] is a self contained, intraoperative, whole blood autotransfusion system that allows simple, effective collection and infusion of a patient's own blood; eliminating the waiting for typing, cross matching, or testing.
Pharmexa said that its strategy was to focus most of the company's financial resources on achieving clinical proof of concept in patients in its HER-2 Protein AutoVac programme, expected in mid-2006.